泽布替尼单药治疗复发或难治性非生发中心弥漫大B细胞淋巴瘤
总缓解率29.3%,完全缓解率17.1%,中位无进展生存期2.8个月,中位总生存期8.4个月。泽布替尼显示 modest 抗肿瘤活性,安全性可控,CD79B和MYD88双突变患者中观察到潜在活性。
要点
- 泽布替尼单药在复发或难治性非生发中心弥漫大B细胞淋巴瘤中总缓解率29.3%,完全缓解率17.1%。
- 中位无进展生存期2.8个月,中位总生存期8.4个月,中位缓解持续时间4.5个月。
- ≥3级不良事件发生率48.8%,未观察到大出血、心房颤动和/或扑动。
核心结论
- 泽布替尼在复发或难治性非生发中心弥漫大B细胞淋巴瘤中显示 modest 抗肿瘤活性,安全性特征与既往研究一致。
- CD79B和MYD88双突变患者中观察到潜在抗肿瘤活性,该类患者对免疫化疗预后较差。
研究设计与样本
- BGB-3111-207研究(NCT03145064)为多中心单臂2期研究。
- 主要终点为总缓解率,次要终点包括无进展生存期和缓解持续时间,总生存期为探索性终点。
主要发现
- 中位随访6.8个月,总缓解率29.3%,完全缓解率17.1%。
- 中位缓解持续时间4.5个月,中位无进展生存期2.8个月,中位总生存期8.4个月。
- 4例患者因不良事件终止治疗,48.8%患者报告≥3级不良事件,未观察到大出血、心房颤动和/或扑动。
- 通过回顾性生物标志物检测,CD79B和MYD88双突变患者中观察到潜在抗肿瘤活性。
关键数值与推荐
- 泽布替尼给药方案为160mg每日两次口服。
- 总缓解率29.3%,完全缓解率17.1%,中位缓解持续时间4.5个月,中位无进展生存期2.8个月,中位总生存期8.4个月。
- ≥3级不良事件发生率48.8%,因不良事件终止治疗4例。
临床怎么用
- 泽布替尼单药可作为复发或难治性非生发中心弥漫大B细胞淋巴瘤的候选治疗,但缓解率有限。
- 未来需关注基于机制的联合治疗和生物标志物驱动的患者选择。
局限性
- 生物标志物分析为回顾性检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The non-germinal center B-cell like (non-GCB) subtype of diffuse large B-cell lymphoma (DLBCL) has poor clinical outcomes. Bruton tyrosine kinase (BTK) inhibitors have established therapeutic activity in B-cell malignancies, with modest activity in DLBCL. Zanubrutinib, a potent and selective BTK inhibitor, was evaluated in patients with relapsed or refractory (R/R) non-GCB DLBCL. The BGB-3111-207 study (NCT03145064) was a multicenter single-arm phase 2 study. Patients received twice-daily oral zanubrutinib, 160 mg, until disease progression or unacceptable toxicity. The primary end point was the overall response rate (ORR). Secondary end points included progression-free survival (PFS) and duration of response (DOR). Overall survival (OS) was an exploratory end point. Forty-one patients were enrolled in China after having progressed or not responded to prior therapy. At data cutoff, 4 patients continued treatment with 37 discontinuations. The median follow-up was 6.8 months, the ORR was 29.3%, and the complete response rate was 17.1%. Median DOR, PFS, and OS were 4.5, 2.8, and 8.4 months, respectively. Adverse events (AEs) leading to treatment discontinuation were reported in 4 patients, and grade ≥ 3 AEs were reported in 48.8% of patients. Major hemorrhage, atrial fibrillation, and/or flutter were not observed. Zanubrutinib demonstrated modest antitumor activity in non-GCB DLBCL, like other BTK inhibitors, as well as a safety profile consistent with previous studies. Through retrospective biomarker testing, potential antitumor activity was observed in patients with both CD79B and MYD88 mutations, who have inferior outcomes to immunochemotherapy. Future studies of zanubrutinib in R/R non-GCB DLBCL will focus on developing mechanism-based treatment combinations and biomarker-driven patient selection.
引用
- Yang H, Xiang B, Song Y, et al. Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma. Blood Adv. 2022. PMID: 34638136. doi:10.1182/bloodadvances.2020003698
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。